Use of direct-acting oral anticoagulants associated with improved survival and bypass graft patency compared with warfarin after infrageniculate bypass

• Published in: Journal of vascular surgery Vol. 77; no. 5; pp. 1453 - 1461
• Main Authors: Ebertz, David P., Bose, Saideep, Smith, Justin A., Sarode, Anuja L., Ambani, Ravi N., Cho, Jae S., Kumins, Norman H., Kashyap, Vikram S., Colvard, Benjamin D.
• Format: Journal Article
• Language: English
• Published: United States Elsevier Inc 01.05.2023
• Subjects: Anticoagulants; Anticoagulation; Blood Vessel Prosthesis Implantation - adverse effects; Direct-acting oral anticoagulant; Factor Xa Inhibitors; Humans; Lower extremity; Peripheral arterial disease; Retrospective Studies; Risk Factors; Treatment Outcome; Vascular Patency; Warfarin; Warfarin - adverse effects; Peripheral arterial disease; Warfarin; Anticoagulation; Lower extremity; Direct-acting oral anticoagulant
• ISSN: 0741-5214; 1097-6809
• DOI: 10.1016/j.jvs.2022.12.012

No consensus has yet been reached regarding the optimal antiplatelet and anticoagulant regimen for patients after lower extremity bypass. Usually, patients who have undergone below-the-knee bypass will begin oral anticoagulation therapy. Historically, the bypass has been with prosthetic conduits and the anticoagulation therapy has been warfarin. However, the use of direct-acting oral anticoagulants (DOACs) has been increasing owing to their relative ease of dosing. The goal of the present study was to evaluate whether a difference exists in the postoperative outcomes for patients who have undergone infrageniculate bypass stratified by the use of on DOACs vs warfarin. The Vascular Quality Initiative infrainguinal bypass database was queried for all patients who had undergone infrageniculate bypass, been anticoagulation naive at baseline, and been discharged with anticoagulation therapy. A survival analysis was performed for patients for ≤2 years postoperatively to determine whether discharge with warfarin vs DOACs was associated with differences in overall mortality, loss of primary patency, risk of amputation, and risk of major adverse limb events (MALE). A multivariable Cox proportional hazards analysis was performed to control for differences in the baseline demographic factors between the two groups. During the study period (2007-2020) 57,887 patients had undergone infrageniculate bypass. Of these patients, 2786 had been anticoagulation naive and discharged with either warfarin (n = 1889) or DOACs (n = 897). Discharge with a DOAC was associated with a lower risk of overall mortality (hazard ratio [HR], 0.62; 95% confidence interval [CI], 0.47-0.83; P = .001), loss of primary patency (HR, 0.74; 95% CI, 0.62-0.87; P < .001), risk of amputation (HR, 0.70; 95% CI, 0.57-0.86; P = .001), and risk of MALE (HR, 0.83; 95% CI, 0.71-0.97; P = .017). Anticoagulation-naive patients who had undergone infrageniculate bypass had had higher rates of overall survival, bypass patency, amputation-free survival, and freedom from MALE when discharged with a DOAC than with warfarin. [Display omitted]